One pill for all: new hope for children with HIV in africa
NCT ID NCT05993767
Summary
This study tested a new dose of three proven HIV medicines (dolutegravir, emtricitabine, and tenofovir alafenamide) in children under 10 years old in Africa. The goal was to find the right dose to create a single, easy-to-take tablet that works for all children, just like adults. Researchers checked the drug levels in the blood and safety over 24 weeks to see if this could become a universal first-line treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine Children's Foundation
Kampala, Uganda
-
Joint Research Centre
Kampala, Uganda
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.